COVID-19 is a risk factor for retinal vein occlusion in younger patients?
DOI: 10.32364/2311-7729-2022-22-1-62-67
A.G. Shchuko1,2,3, M.V. Akulenko1, T.N. Yur’eva1,2,3
1Irkutsk Branch of the S. Fyodorov Eye Microsurgery Federal State Institution, Irkutsk, Russian Federation
2Irkutsk State Medical Academy of Professional Education — Branch of the Russian Medical Academy of Continuous Professional Education, Irkutsk, Russian Federation
3Irkutsk State Medical University, Irkutsk, Russian Federation
Retinal vein occlusions (RVOs) are thought to have more favorable outcomes in patients under-50 due to spontaneous regression. However, 20% develop severe neovascularization. In most cases, the causal link of occlusion remains elusive. Some authors report on clinical presentations typical for RVOs in the COVID-19 infection due to hypercoagulation. Management of younger patients with RVO required a complex diagnostic approach to assess systemic risk factors and obligatory evaluation of baseline retinal ischemia using fluorescein angiography (FA) or optical coherence tomography angiography (OCTA). Clinical criteria of escalating retinal ischemia are decreased central visual acuity, macular edema, increased area of ischemia, and (later) retinal and/or anterior segment neovascularization. We describe a young man with RVO after the COVID-19 infection. The COVID-19 infection had no significant effect on hemostasis parameters in this patient. Meanwhile, the COVID-19 infection cannot be ruled out as an aggravating factor in a patient with a genetic predisposition to (micro)vascular occlusions.
Keywords: OCTA, retinal neovascularization, retinal vein occlusion, coagulogram, COVID-19.
For citation: Shchuko A.G., Akulenko M.V., Yur’eva T.N. COVID-19 is a risk factor for retinal vein occlusion in younger patients? Russian Journal of Clinical Ophthalmology. 2022;22(1):62–67 (in Russ.). DOI: 10.32364/2311-7729-2022-22-1-62-67.
About the authors:
1,2,3Andrey G. Shchuko — Dr. Sc. (Med.), Professor, Director; Head of the Department of Ophthalmology; Head of the Department of Ocular Diseases; ORCID iD 0000-0002-4264-4408.
1Mikhail V. Akulenko — C. Sc. (Med.), ophthalmologist; ORCID iD 0000-0003-4905-3835.
1,2,3Tatyana N. Yur’eva — Dr. Sc. (Med.), Professor, Deputy Director for Scientific Work; professor of the Department of Ophthalmology; professor of the Department of Ocular Diseases; ORCID iD 0000-0003-0547-7521.
1Irkutsk Branch of the S. Fyodorov Eye Microsurgery Federal State Institution, 337, Lermontov str., Irkutsk, 664033, Russian Federation.
2Irkutsk State Medical Academy of Professional Education — Branch of the Russian Medical Academy of Continuous Professional Education, 100, Yubileinyy subdistrict, Irkutsk, 664049, Russian Federation.
3Irkutsk State Medical University, 1, Krasnogo Vosstaniya str., Irkutsk, 664003, Russian Federation.
Contact information: Michael V. Akulenko, e-mail: dr9063e@gmail.com.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 21.12.2020.
2. Budzinskaya M.V., Mazurina N.K., Egorov A.E. et al. Retinal vein occlusion management algorithm. Part 1. Classification, diagnosis, and acute-stage treatment. The Russian Annals of Ophthalmology. 2015;6:51–56 (in Russ.). DOI: 10.17116/oftalma2015131651-56.
3. Hayreh S., Rojas P., Podhajsky P. et al. Ocular neovascularization with retinal vascular occlusion-III. Incidence of ocular neovascularization with retinal vein occlusion. Ophthalmology. 1983;5(90):488–506. DOI: 10.1016/s0161-6420(83)34542-5.
4. Rogers S., McIntosh R., Cheung N. et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;2(117):313–319. DOI: 10.1016/j.ophtha.2009.07.017.
5. Li J., Paulus Y.M., Shuai Y. et al. New Developments in the Classification, Pathogenesis, Risk Factors, Natural History, and Treatment of Branch Retinal Vein Occlusion. J Ophthalmol. 2017;2017:4936924. DOI: 10.1155/2017/4936924.
6. Kuo J. Z.-Ch., Lai Ch.-Ch., Ong F. Sh.-Ch. et al. Central retinal vein occlusion in a young Chinese population: risk factors and associated morbidity and mortality. Retina. 2010;30(3):479–484. DOI: 10.1097/IAE.0b013e3181b9b3a0.
7. Lam H.D., Lahey J.M., Kearney J.J. et al. Young patients with branch retinal vein occlusion: a review of 60 cases. Retina 2010;30:1520–1523.
8. Shchuko A., Zlobin I., Iureva T. Prognostic Criteria of Anti-VEGF Therapy Efficacy in Retinal Vein Occlusion. Ophthalmic Res. 2016;56(suppl. 1):18.
9. Fong A., Schatz H., McDonald H. et al. Central retinal vein occlusion in young adults (papillophlebitis). Retina. 1992;12:3–11. DOI: 10.1097/00006982-199212010-00002.
10. Hayreh S., Zimmerman M. Fundus changes in central retinal vein occlusion. Retina. 2015;1(35):29–42. DOI: 10.1097/IAE.0000000000000256.
11. Sheth J.U., Narayanan R., Goyal J., Goyal V. Retinal vein occlusion in COVID-19. A novel entity. Ind J Ophthalmol. 2020;68(10):2291–2293. DOI: 10.4103/ijo.IJO_2380_20.
12. Invernizzi A., Pellegrini M., Messenio D. et al. Impending Central Retinal Vein Occlusion in a Patient with Coronavirus Disease 2019 (COVID-19). Ocul Immunol Inflam. 2020;28(8):1290–1292. DOI: 10.1080/09273948.2020.1807023.
13. Shchuko A.G., Zlobin I.V., Iureva T.N., Mikhalevich I.M. Comprehensive assessment of risk factors for retinal vein occlusion and derivation of classification criteria for retinal ischemia. The Russian Annals of Ophthalmology. 2014;5:54–59 (in Russ.).
14. Shchuko A.G., Akulenko M.V., Iureva T.N. et al. Transpupillary thermotherapy of the optic nerve as a method of choice in the treatment of the central retinal vein occlusion. Fyodorov Journal of Ophthalmic Surgery. 2014;(3):42–47 (in Russ.).
15. Kumar A., Narayan R.K., Kumaria C. et al. SARS-CoV-2 cell entry receptor ACE2 mediated endothelial dysfunctionleads to vascular thrombosis in COVID-19 patients. Med Hypotheses. 2020;145:110320. DOI: 10.1016/j.mehy.2020.110320.
16. Joussen A., Gardner T., Kirchhof B. et al. Retinal Vascular Disease. Heidelberg (Germany): Springer-Verlag; 2007.
17. Lip P.L., Belgore F., Blann A.D. et al. Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: relationship to endothelial dysfunction and laser treatment. Invest Ophthalmol Vis Sci. 2000;41(8):2115–2119. PMID: 10892852.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Распечатать